199,233 Shares in Maplight Therapeutics, Inc. $MPLT Bought by Board of Trustees of The Leland Stanford Junior University

Board of Trustees of The Leland Stanford Junior University purchased a new position in Maplight Therapeutics, Inc. (NASDAQ:MPLT) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 199,233 shares of the company’s stock, valued at approximately $3,500,000. Maplight Therapeutics comprises about 0.7% of Board of Trustees of The Leland Stanford Junior University’s holdings, making the stock its 7th largest holding. Board of Trustees of The Leland Stanford Junior University owned about 0.44% of Maplight Therapeutics at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Strs Ohio bought a new stake in shares of Maplight Therapeutics in the fourth quarter worth $53,000. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Maplight Therapeutics in the fourth quarter worth $70,000. New York State Common Retirement Fund bought a new stake in shares of Maplight Therapeutics in the fourth quarter worth $93,000. MetLife Investment Management LLC bought a new stake in shares of Maplight Therapeutics in the fourth quarter worth $172,000. Finally, Walleye Capital LLC bought a new stake in shares of Maplight Therapeutics in the fourth quarter worth $205,000.

Insider Activity at Maplight Therapeutics

In other news, CEO Christopher A. Kroeger sold 118,235 shares of the business’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $27.19, for a total transaction of $3,214,809.65. Following the completion of the transaction, the chief executive officer owned 1,394,094 shares of the company’s stock, valued at approximately $37,905,415.86. The trade was a 7.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider James Woodruff Lillie sold 24,811 shares of the business’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $28.76, for a total transaction of $713,564.36. Following the transaction, the insider directly owned 243,450 shares of the company’s stock, valued at approximately $7,001,622. This trade represents a 9.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 495,244 shares of company stock valued at $14,079,461. Company insiders own 3.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on MPLT. Wall Street Zen lowered shares of Maplight Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Stifel Nicolaus boosted their target price on shares of Maplight Therapeutics from $28.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, June 1st. Canaccord Genuity Group began coverage on shares of Maplight Therapeutics in a research note on Thursday, March 19th. They set a “buy” rating and a $35.00 target price for the company. UBS Group began coverage on shares of Maplight Therapeutics in a research note on Tuesday, May 26th. They set a “buy” rating and a $48.00 target price for the company. Finally, Needham & Company LLC began coverage on shares of Maplight Therapeutics in a research note on Wednesday, April 8th. They set a “buy” rating and a $37.00 target price for the company. Three investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Maplight Therapeutics has an average rating of “Buy” and a consensus target price of $37.78.

Maplight Therapeutics Price Performance

MPLT stock opened at $27.96 on Tuesday. Maplight Therapeutics, Inc. has a 1-year low of $12.24 and a 1-year high of $33.28. The firm has a fifty day moving average price of $28.44 and a two-hundred day moving average price of $21.63. The firm has a market cap of $1.19 billion and a price-to-earnings ratio of -0.68.

Maplight Therapeutics (NASDAQ:MPLT) last released its earnings results on Thursday, May 14th. The company reported ($1.34) earnings per share for the quarter, missing the consensus estimate of ($0.91) by ($0.43). As a group, analysts expect that Maplight Therapeutics, Inc. will post -5.04 EPS for the current fiscal year.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.